{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:07:39Z","timestamp":1790712459749,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T00:00:00Z","timestamp":1500336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric Antigen Receptor (CAR) T-cells are T-cells with recombinant receptors targeted to tumor antigens. CAR-T cell therapy has emerged as a mode of immunotherapy and is now being extensively explored in hematologic cancer. In contrast, CAR-T cell use in solid tumors has been hampered by multiple obstacles. Several approaches have been taken to circumvent these obstacles, including the regional delivery of CAR-T cells. Regional CAR-T cell delivery can theoretically compensate for poor T-cell trafficking and tumor antigen specificity while avoiding systemic toxicity associated with intravenous delivery. We reviewed completed clinical trials for the treatment of glioblastoma and metastatic colorectal cancer and examined the data in these studies for safety, efficacy, and potential advantages that regional delivery may confer over systemic delivery. Our appraisal of the available literature revealed that regional delivery of CAR-T cells in both glioblastoma and hepatic colorectal metastases was generally well tolerated and efficacious in select instances. We propose that the regional delivery of CAR-T cells is an area of potential growth in the solid tumor immunotherapy, and look towards future clinical trials in head and neck cancer, mesothelioma, and peritoneal carcinomatosis as the use of this technique expands.<\/jats:p>","DOI":"10.3390\/cancers9070092","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T10:33:14Z","timestamp":1500373994000},"page":"92","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy"],"prefix":"10.3390","volume":"9","author":[{"given":"Praveen","family":"Sridhar","sequence":"first","affiliation":[{"name":"Department of Surgery, Boston University, Boston, MA 02118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Petrocca","sequence":"additional","affiliation":[{"name":"Department of Surgery, Boston University, Boston, MA 02118, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR-T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_2","first-page":"1","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Oncolytics"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhang, E., and Xu, H. (2017). A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J. Hematol. Oncol., 1\u201311.","DOI":"10.1186\/s13045-016-0379-6"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-2218","article-title":"T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo","volume":"20","author":"Geldres","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer- Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Prapa, M., Caldrer, S., Spano, C., Bestagno, M., Golinelli, G., Grisendi, G., Petrachi, T., Conte, P., Horwitz, E.M., and Paolucci, P. (2015). A novel anti-GD2\/4\u20131BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget, 6.","DOI":"10.18632\/oncotarget.4670"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Li, H., and Zhao, Y. (2017). Increasing the safety and ef fi cacy of chimeric antigen receptor T cell therapy. Protein Cell.","DOI":"10.1007\/s13238-017-0411-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"CCR FOCUS Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Adusumilli, P.S., Cherkassky, L., Villena-vargas, J., Servais, E., Plotkin, J., Jones, D.R., and Sadelain, M. (2015). Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med., 6.","DOI":"10.1126\/scitranslmed.3010162"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ra2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"1","article-title":"Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma","volume":"21","author":"Choi","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Han, J., Chu, J., Chan, W.K., Zhang, J., Wang, Y., Cohen, J.B., Victor, A., Meisen, W.H., Kim, S., and Grandi, P. (2015). CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep.","DOI":"10.1038\/srep11483"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Non-invasive detection of therapeutic cytolytic T Cells in patients with [18-F]FHBG positron emission tomography in a glioma patient","volume":"6","author":"Yaghoubi","year":"2009","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_20","first-page":"260a","article-title":"A phase I\/II study of hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (DEX) with systemic irinotecan (CPT-11) for unresectable hepatic metastases from colorectal cancer","volume":"19","author":"Paty","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2005.07.100","article-title":"Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer","volume":"23","author":"Kemeny","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/mt.2014.148","article-title":"T-Cell immunotherapy: Looking forward","volume":"22","author":"Kiem","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3748\/wjg.v17.i36.4067","article-title":"Current treatment for colorectal liver metastases","volume":"17","author":"Misiakos","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Guha, P., Reha, J., and Katz, S.C. (2016). Immunosuppression in liver tumors: Opening the portal to effective immunotherapy. Nat. Publ. Gr.","DOI":"10.1038\/cgt.2016.54"},{"key":"ref_26","unstructured":"U.S. National Institutes of Health (2017, May 08). Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) with Yttrium-90 Sir-Spheres\u00ae for CEA-Expressing Liver Metastases, Available online: http:\/\/clinicaltrials.gov\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u201cT4 immunotherapy\u201d of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.4049\/jimmunol.1301523","article-title":"Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: Identifying a window of therapeutic opportunity?","volume":"191","author":"Davies","year":"2013","journal-title":"J. Immunol."},{"key":"ref_29","unstructured":"U.S. National Institutes of Health (2017, May 08). Malignant pleural disease treated with autologous T-cells genetically engineered to target the cancer-cell surface antigen mesothelin, Available online: http:\/\/clinicaltrials.gov\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/molmed.2011.00493","article-title":"Flexible Targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells","volume":"18","author":"Davies","year":"2012","journal-title":"Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"Papa","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/mt.2014.28","article-title":"Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells","volume":"22","author":"Waks","year":"2014","journal-title":"Mol. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/92\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:43:04Z","timestamp":1760208184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/9\/7\/92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["cancers9070092"],"URL":"https:\/\/doi.org\/10.3390\/cancers9070092","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]}}}